<DOC>
	<DOC>NCT00320450</DOC>
	<brief_summary>The purpose of this research is to find out how effective and safe SB-681323 will be in the treatment of RA when it is added to standard anti-rheumatic treatments.</brief_summary>
	<brief_title>SB-681323 In Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Females cannot be pregnant or lactating. Must use defined contraceptive methods if of childbearing potential. BMI range: 18.535.0 kg/m2. Diagnosis of RA (rheumatoid arthritis) according to revised 1987 American College of Rheumatology (ACR) criteria. If other RAmedication is used: DiseaseModifying AntiRheumatic Drug (DMARDS) must be stable for at least 8 weeks before first trial visit. If other oral antiRA therapies are used, these must have been stable at least 4 weeks before first trial visit. If Methotrexate medication is used as RAtherapy, Folate supplement must be taken with stable red cell folate levels. Must give informed consent. Must abstain from alcohol during the trial participation. Nonresponder on biological RA treatment. Has a positive alcohol screen. Any history of liver disease. Positive Hepatitis B surface antigen or Hepatitis C antibody result within 3 months of screening. Have any significant disease that places the subject at unacceptable risk as a participant in this trial. Acute infection. History of active tuberculosis. History of repeated or chronic infection. History of malignancy. History of HIV or other immunosuppressive diseases. Participated in a clinical trial within the last 3 months for nonbiological therapies and 6 months for biological therapies. Uncontrolled diabetes or psoriasis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>SB-681323</keyword>
	<keyword>CRP</keyword>
	<keyword>Rheumatoid Arthritis SB-681323 CRP RA</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
</DOC>